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ABSTRACT
Atypical teratoid rhabdoid tumor (AT/RT) is among the most fatal of all pediatric 
brain tumors. Aside from loss of function mutations in the SMARCB1 (BAF47/INI1/
SNF5) chromatin remodeling gene, little is known of other molecular drivers of AT/
RT. LIN28A and LIN28B are stem cell factors that regulate thousands of RNAs and 
are expressed in aggressive cancers. We identified high-levels of LIN28A and LIN28B 
in AT/RT primary tumors and cell lines, with corresponding low levels of the LIN28-
regulated microRNAs of the let-7 family. Knockdown of LIN28A by lentiviral shRNA 
in the AT/RT cell lines CHLA-06-ATRT and BT37 inhibited growth, cell proliferation 
and colony formation and induced apoptosis. Suppression of LIN28A in orthotopic 
xenograft models led to a more than doubling of median survival compared to empty 
vector controls (48 vs 115 days). LIN28A knockdown led to increased expression of 
let-7b and let-7g microRNAs and a down-regulation of KRAS mRNA. AT/RT primary 
tumors expressed increased mitogen activated protein (MAP) kinase pathway activity, 
and the MEK inhibitor selumetinib (AZD6244) decreased AT/RT growth and increased 
apoptosis. These data implicate LIN28/RAS/MAP kinase as key drivers of AT/RT 
tumorigenesis and indicate that targeting this pathway may be a therapeutic option 
in this aggressive pediatric malignancy.
INTRODUCTION
Atypical teratoid rhabdoid tumor (AT/RT) is one of 
the most aggressive pediatric tumors of the central nervous 
system [1]. Despite the use of intensive multimodality 
treatment, the overall survival rate is less than 50 percent 
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[2]. Due to its aggressive nature and resistance to existing 
treatment, there is a significant need for novel therapeutic 
targets in AT/RT.
Deletions and mutations of the SMARCB1 (BAF47/
INI1/SNF5) gene are the hallmark of AT/RT tumors, yet 
there are no other recurrent genetic abnormalities [3-5]. 
SMARCB1 is a component of the SWI/SNF chromatin 
remodeling complex, and loss of function of SMARCB1 
can dysregulate thousands of genes across the genome 
[6]. While mutations at this locus are the defining genetic 
alteration of AT/RT, much of the biology contributing to 
the development and aggressiveness of AT/RT is poorly 
understood [7].
Another distinguishing characteristic of AT/RT is a 
heterogeneous histologic appearance with characteristics 
of several distinct cell lineages, suggesting that stem cells 
may play a role in the tumorigenesis of AT/RT [1]. Primary 
AT/RT tumors express stem cell factors such as SAL4, 
KLF4, and MUSHASHI [8]. LIN28A is a stem cell factor 
that was first discovered as a regulator of development, and 
it has since been implicated in multiple aggressive cancers 
[9]. LIN28A expression is high in embryonic stem cells 
and maintains pluripotency by inhibiting let-7 induced 
differentiation [10]. The let-7 family of microRNAs 
in turn acts as tumor suppressors, through inhibition of 
oncogenes including KRAS, HMGA2, and MYC. We have 
previously identified LIN28A as a driver of proliferation 
and invasion in adult and pediatric glioblastoma [11]. As 
part of a screen of a series of pediatric brain tumors for 
LIN28A expression, we identified high level LIN28A 
expression in AT/RT samples by immunohistochemistry. 
We hypothesized that LIN28A and LIN28B might 
contribute to AT/RT tumorigenicity by upregulating at 
the RNA level many oncogenic proteins which contribute 
to AT/RT growth, invasion, and metabolism. We report 
that LIN28A and LIN28B are highly expressed in AT/
RT primary tumors and cell lines, and that knockdown of 
LIN28A suppresses AT/RT growth and tumorigenicity and 
leads to downregulation of KRAS mRNA. Examination of 
AT/RT primary tumor tissue shows expression of the RAS 
effector phospho-ERK in 77% of AT/RT. We demonstrate 
that the MEK inhibitor selumetinib also suppresses AT/
RT cell line growth and induces apoptosis, phenocopying 
LIN28A loss. These results indicate activation of a LIN28/
RAS/MAP kinase pathway in AT/RT and suggest that 
MEK inhibitors may be effective in this tumor. 
RESULTS
LIN28A and LIN28B are highly expressed in 
primary AT/RT tumor samples and cell lines
We have previously identified high-level expression 
of LIN28A and LIN28B in approximately 30 percent 
of pediatric and adult glioblastoma [11]. LIN28B is 
expressed in a poor-prognosis subset of medulloblastoma, 
[12] and a subtype of primitive neuroectodermal tumors 
has increased expression of LIN28A [13, 14]. By 
immunohistochemistry (IHC), we found that 19/24 AT/
RT were positive for LIN28A (79%). Approximately 30% 
of AT/RT have moderate or high-level LIN28A staining 
(Figure 1A). Normal cortex did not show any LIN28A 
expression by IHC (Supplemental Figure 1A). We were 
not able to interrogate AT/RT at the level of histology for 
LIN28B, due to a lack of LIN28B antibodies validated 
for IHC. We next investigated the mRNA expression of 
LIN28A and LIN28B in AT/RT tumors by qPCR, using 
pediatric pilocytic astrocytoma (PA) as a comparator. 
These tumor types have not been systematically 
interrogated for LIN28 expression and have relatively few 
genomic alterations. We found that primary AT/RT tumors 
expressed high level LIN28A and LIN28B mRNA (Figure 
1B, p=0.002 for LIN28A and p=0.006 for LIN28B by 
Mann-Whitney test) compared to PA tumors. Of the 23 AT/
RT tumors that were evaluated by qPCR for both LIN28A 
and LIN28B expression, 6 tumors had predominantly high 
LIN28A expression, 5 tumors had predominantly high 
LIN28B expression, 7 tumors had equivalent high-level 
expression of both LIN28A and LIN28B, and 5 tumors had 
low-level expression of LIN28A and LIN28B, comparable 
to levels found in PA. In total, 18/23 AT/RT (78%) showed 
increased expression of LIN28A, LIN28B or both. 
LIN28A is known to negatively regulate the tumor-
suppressing microRNAs of the let-7 family, and when we 
performed Nanostring assay for let-7 family members, 
we found that AT/RT tumors had significantly lower let-7 
levels than PA samples (Figure 1C, p<0.01 for all let-7 
species by Mann-Whitney test). 
When we examined medulloblastoma primary 
tumors for comparison of LIN28A expression, we 
found that 24 percent of these aggressive pediatric brain 
malignancies (15/63 tumors) expressed increased levels of 
LIN28A by IHC compared to normal brain (Supplemental 
Figure 1A). By qPCR we found increased LIN28B 
expression in 16/31 (52%) of medulloblastoma samples, 
compared to normal pediatric cerebellum (Supplemental 
Figure 1B). This is consistent with previous reports of 
increased LIN28B expression in medulloblastoma [12].
AT/RT cell lines express high levels of LIN28A 
and LIN28B
We found that of the 6 AT/RT cell lines in our 
laboratory, 2 expressed LIN28A at high level by western 
blot, and 3 expressed LIN28B at high level (Figure 2A). 
By qPCR, we detected LIN28A in CHLA-02, indicating 
that in this panel, 100% of AT/RT express LIN28A or 
LIN28B (data not shown). 
Oncotarget3167www.impactjournals.com/oncotarget
Knockdown of LIN28A inhibits AT/RT growth 
and proliferation 
To examine the importance of LIN28A in the 
tumorigenicity of AT/RT, we used short hairpin RNA 
constructs packaged in lentivirus to inhibit LIN28A 
protein expression. Effective LIN28A knockdown by two 
distinct shRNA constructs was confirmed by western blot 
(Figure 2B) in two cell lines derived from primary human 
AT/RT tumors (BT37 and CHLA-06). 
Knockdown of LIN28A resulted in a significant 
reduction of growth in both BT37 and CHLA-06. 
Compared to pLKO empty vector, in BT37 we detected a 
50% reduction in growth at day 8 (Figure 2C, p=0.003 for 
sh800 vs pLKO control and p=0.004 for sh803 vs pLKO, 
by Student’s t-test). Similarly, in CHLA-06 we detected 
a 60% inhibition in growth with LIN28A knockdown by 
MTS assay (Figure 2C, p=0.0004 for sh802 vs pLKO 
control and p=0.009 for sh803 vs pLKO, by Student’s 
t-test). In both BT37 and CHLA-06 LIN28A-shRNA 
cells, we observed a 65% reduction in the percentage of 
proliferating cells after LIN28A knockdown, as measured 
by BrdU incorporation, compared to pLKO empty vector 
Fig.1: Increased expression of LIN28A and LIN28B and decreased let-7 expression in AT/RT. A. LIN28A 
immunohistochemistry performed on 24 AT/RT primary tumors revealed high-level LIN28A expression in more than 30 percent of AT/RT 
(moderate plus high staining). Normal brain did not show any LIN28A staining. B. We identified increased LIN28A and LIN28B mRNA in 
AT/RT compared to pediatric pilocytic astrocytoma (PA) samples by qPCR. For LIN28A, we compared 29 AT/RT primary tumors to 11 PA 
samples. For LIN28B, we compared 23 AT/RT tumors to 7 PA samples. Data is presented in a box and whisker plot showing the median 
and range of expression of LIN28A (left) and LIN28B (right). Note the log scale. Asterisk indicates p=0.0002 for LIN28A and p=0.0006 for 
LIN28B by Mann-Whitney test. C. AT/RT express decreased amounts of let-7 species compared to pediatric PA samples as measured by 
Nanostring assay. Note the log scale. * indicates p<0.0001, ** indicates p<0.001, *** indicates p<0.01 by Mann-Whitney test. For each 
let-7 Nanostring assay, we compared 26 AT/RT tumors to 18 PA tumors 
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controls (Figure 2D, for BT37, p=0.0004 for sh800 
vs pLKO, p=0.00008 for sh803 vs pLKO; CHLA-06, 
p=0.00005 for sh802 vs pLKO, p=0.0001 for sh803 vs 
pLKO by Student’s t-test).
Knockdown of LIN28A suppresses AT/RT 
clonogenic growth and tumorigenicity
To assess the role of LIN28A in the clonogenicity 
of AT/RT cell lines, LIN28-shRNA transduced cells and 
pLKO control cells were plated as single cells in soft agar 
and allowed to grow for 2 weeks. Compared to control, 
colonies formed by BT37 and CHLA-06 cells with 
LIN28A knockdown were reduced by between 50 and 90 
percent (Figure 3A – For BT37 p=0.0002 sh800 vs pLKO, 
p=0.0001 sh803 vs pLKO; for CHLA-06 p= 0.009 sh802 
vs pLKO, p=0.06 sh803 vs pLKO). We further tested the 
ability of LIN28A deficient AT/RT cells to form tumors 
by injecting shLIN28A-transduced or pLKO control 
transduced BT37 cells into brains of immunodeficient 
mice. Within two months of injection, all mice injected 
with BT37 pLKO control had died from malignant tumors 
(Figure 3B). The median survival of mice (n=4 in each 
Fig.2: Lentiviral short hairpin RNA knockdown of LIN28A suppresses AT/RT growth and proliferation. A. Western blot 
showing increased expression of LIN28A (top) and LIN28B (bottom) in AT/RT cell lines. CHLA02 expresses LIN28A by qPCR, but at a 
level that is not detectable by western blot (data not shown). B. Western blot showing knockdown of LIN28A in AT/RT cell lines BT37 and 
CHLA-06 after lentiviral infection with two different shRNA constructs. pLKO is a control, empty-vector construct. Numbers under the 
blot indicate the relative change in intensity of LIN28A band, normalized to ACTIN, as measured by densitometry. C. MTS growth assay 
showing suppression of growth by knockdown of LIN28A in BT37 (top) and CHLA-06 (bottom). Asterisk = p<0.005 by t-test comparing 
each shRNA to pLKO. D. Suppression of proliferation as measured by BrdU incorporation after knockdown of LIN28A in BT37 and 
CHLA-06. At left is representative immunofluorescence showing decreased BrdU incorporation. At right is a graph showing quantification 
of percent BrdU positivity. Asterisk = p<0.0005 by t-test comparing each shRNA to pLKO 
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group) injected with BT37 cells with LIN28A knockdown 
was 115 days compared to 48 days for mice injected with 
BT37 pLKO control transduced cells (p=0.007 by log rank 
test). There was no significant difference in microscopic 
appearance of the tumors that formed in either group, and 
we determined by LIN28A immunohistochemistry that 
LIN28A knockdown tumors expressed LIN28A at a level 
equal to that found in pLKO tumors (data not shown). 
Suppression of LIN28 induces apoptosis in AT/RT 
cell lines
 We investigated the mechanism by which loss of 
LIN28A suppressed the growth of AT/RT cell lines. We 
found that LIN28A knockdown in BT37 and CHLA-06 
cells led to a 4 to 6 fold increase in the percentage of cells 
expressing cleaved caspase 3 (CC3) compared to controls, 
as measured by immunofluorescence (Figure 4A – For 
BT37 p=0.0005 sh800 vs pLKO and p=0.0001 for sh803 
vs pLKO; for CHLA-06 p=0.004 sh802 vs pLKO and 
p=0.009 sh803 vs pLKO). We also observed an induction 
in the expression of cleaved PARP (cPARP) protein in 
CHLA-06 and BT37 cells with LIN28A knockdown 
by western blot (Figure 4B). Levels of cell death were 
further assessed with cell cycle analysis, and we observed 
an increase in the sub-G1 population in both BT37 and 
CHLA-06 LIN28A-shRNA cells compared to controls 
(Supplemental Figure 2). 
Fig.3: Knockdown of LIN28A suppresses AT/RT clonogenicity and tumorigenicity. A. Photomicrograph (100x) showing 
colony formation after LIN28A knockdown in CHLA-06 and BT37. Right is quantification of colonies greater than 50 µM. Asterisk = 
p<0.01 by Student’s t-test comparing shRNA to pLKO control. For CHLA-06 sh803 vs pLKO, p = 0.06. B. Kaplan-Meier curve showing 
survival after injection of BT37 cells into the deep gray matter of immunodeficient mice. The median survival of mice (n=4 in each 
group) injected with BT37 cells with LIN28A knockdown was 115 days compared to 48 days for mice injected with BT37 pLKO control 
transduced cells (p=0.007 by log rank test).
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Knockdown of LIN28A results in an upregulation 
of let-7 micro-RNAs and suppression of KRAS 
We next interrogated the effect of LIN28A 
knockdown on the tumor suppressing let-7 microRNAs. 
We observed an increase in the expression of let-7g and 
let-7b after LIN28A knockdown in both BT37 and CHLA-
06 cells compared to pLKO empty vector controls (Figure 
4C). We assessed the effect of LIN28A knockdown on 
potential targets of the let-7 miRNAs by qPCR. Although 
we did not detect a decrease in the expression of MYC, 
HMGA2 or IGF2 (data not shown), we did observe a 
reduction in the expression of KRAS mRNA in BT37 and 
CHLA-06 cells with LIN28A knockdown (Figure 4D). 
Suppression of LIN28A expression led to decreased levels 
of phospho-ERK in CHLA-06 cells (Supplemental Figure 
3). 
Fig.4: Suppression of LIN28A leads to upregulation of let-7 microRNAs, induction of apoptosis, and downregulation 
of KRAS. A. (Left) Knockdown of LIN28A leads to apoptosis as measured by cleaved caspase 3 (CC3) immunofluorescence in BT37 
(top) and CHLA-06 (bottom) cells. Bar graphs (right) show quantification of 3 separate experiments. Asterisk = p<0.01 by Student’s t-test 
comparing each shRNA to pLKO B. Western blot showing upregulation of cleaved PARP (cPARP), an indicator of apoptosis, after LIN28A 
knockdown in BT37 (left) and CHLA-06 (right). Numbers under the blot indicate the relative change in cPARP intensity, normalized to 
ACTIN, as measured by densitometry. C. LIN28A knockdown leads to upregulation of let-7b and let-7g as measured by qPCR in BT37 
(left) and CHLA-06 (right). Results are from a representative experiment, which was repeated with similar results. Error bars represent the 
standard deviations of the representative experiment. D. Reduced expression of KRAS as measured by qPCR after LIN28A knockdown 
in BT37 (left) and CHLA-06 (right). Graphs represent averaged results from two separate experiments. Error bars represent the standard 
deviations of all qPCR wells for each condition (N=6).
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AT/RT primary tumors show high level phospho-
ERK activation
We hypothesized that the RAS pathway may 
be important for AT/RT growth. We determined by 
immunohistochemistry on 22 primary human AT/RT 
tumors that 86% of AT/RT expressed phospho-ERK, a key 
readout of MAP kinase pathway activation (Figure 5A). 
While some tumors had diffuse high-level staining for 
phospho-ERK, others had more patchy immunoreactivity. 
Of those showing activated ERK, 37% (7 out of 19 
tumors) showed intermediate or high level expression. 
There was a positive correlation between pERK and 
LIN28A expression (R=0.57, p=0.009 by Spearman 
correlation). 
Targeting the MAP kinase pathway suppresses 
AT/RT growth and induces apoptosis
We disrupted the RAS/MAP kinase pathway using 
selumetinib, a MEK inhibitor in phase I and II clinical 
trials in children with brain tumors (NCT01089101). 
Selumetinib efficiently blocked ERK activation in AT/RT 
cell lines (Figure 5B) using standard doses [15]. Treatment 
Fig.5: Inhibition of the MAP kinase pathway with MEK inhibitor selumetinib suppresses the growth and proliferation 
of AT/RT cells and induces apoptosis. A. Immunohistochemistry showing high expression of phospho-ERK in AT/RT. Representative 
400X photomicrographs of phospho-ERK staining on an AT/RT primary tumor tissue microarray containing 22 evaluable tumors. Tumor 
scored as no staining on the left, followed by low, intermediate, and high staining. Below the images is indicated the percentage of the 
total number of AT/RT tumors that fell into the respective intensity. B. Western blot showing that selumetinib efficiently inhibits ERK 
phosphorylation in AT/RT. C. MTS plot showing that selumetinib inhibits the growth of BT37 (left) and CHLA-06 (right). Asterisk = 
p<0.01 by t-test, compared to DMSO treated cells. D. Immunofluorescence showing decreased BrdU incorporation in BT37 and CHLA-06 
cells after treatment with selumetinib. Quantification of BrdU incorporation is at right. Asterisk = p<0.01 by t-test comparing selumetinib 
to DMSO control. E. Induction of apoptosis after selumetinib treatment as measured by cleaved caspase 3 (CC3) immunofluorescence. 
Quantification of BrdU incorporation is at right. Asterisk = p<0.05 by t-test comparing selumetinib to DMSO control. 
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with selumetinib for 5 days suppressed the growth of 
BT37 and CHLA-06 (Figure 5C, for BT37 p=0.003 for 
1 uM and p=0.001 for 10 uM vs DMSO control; for 
CHLA-06 p=0.009 for 1 uM and 10uM vs DMSO control 
by t-test). We obtained similar results using the LIN28B-
expressing BT12 AT/RT cell line (p=0.00009 for 10 uM vs 
DMSO control by t-test) (Supplemental Figure 4). 
We observed a 50 percent or greater decrease in 
proliferation, as measured by BrdU incorporation, after 
4 days of treatment with selumetinib in both BT37 and 
CHLA-06 cells (Figure 5D – for BT37 p=0.008 for 
1uM and p=0.004 for 10 uM vs DMSO; for CHLA-06 
p=0.005 for 1uM and p=0.009 for 10 uM vs DMSO by 
t-test). MEK inhibition caused a quadrupling or more of 
apoptosis in both AT/RT cell lines, as measured by CC3 
immunofluorescence after 4 days of selumetinib treatment 
(Figure 5E - for BT37 p=0.02 for 1uM and p=0.001 for 10 
uM vs DMSO; for CHLA-06 p=0.001 for 1uM and p=0.01 
for 10 uM vs DMSO by t-test ). Levels of cell death were 
further assessed with cell cycle analysis, and we observed 
an increase in the sub-G1 population in both BT37 and 
CHLA-06 after treatment with selumetinib (Supplemental 
Figure 5).
DISCUSSION
A greater understanding of molecular abnormalities 
contributing to the development of AT/RT is essential 
to the improvement of therapeutic options. However, 
multiple genome-wide analyses have yielded no reports 
of consistent genetic aberrations in addition to mutations 
in the SMARCB1 gene [3, 4]. Our study investigated the 
molecular biology underlying the tumorigenicity of AT/
RT.
We found frequent overexpression of the cell-
reprogramming factors LIN28A and LIN28B in AT/RT 
primary tumor samples and cell lines. In total, 18/23 
(78%) of AT/RT tumors showed increased expression of 
LIN28A and/or LIN28B by qPCR.Our data together with 
recent reports of increased HMGA2 expression in AT/RT 
suggest a broad reliance on the LIN28/HMGA2 pathway 
in this tumor [16]. 
Increased expression of LIN28 and HMGA2 
are consistent with reports of the role of this pathway 
in other aggressive tumors [9]. In brain tumors, we 
recently reported that LIN28A promotes invasion and 
tumorigenesis in glioblastoma in part through upregulation 
of HMGA2 [11]. LIN28B expression is a poor prognostic 
factor in medulloblastoma [12], LIN28A is associated with 
worse prognosis in primitive neuro-ectodermal tumor [13, 
14], and LIN28A and LIN28B are known to be expressed 
in germ cell tumors [17]. Our finding of high-level 
LIN28A expression in 30 percent of AT/RT is consistent 
with results of other groups who have performed IHC on 
AT/RT for LIN28A [18-20]. The experiments described 
here are the first to our knowledge to investigate the 
functional significance of the LIN28 pathway in AT/
RT and indicate that LIN28 is important for the overall 
growth, proliferation, clonogenicity and tumorigenicity of 
this aggressive tumor.
In orthotopic xenograft experiments, we found that 
the BT37 tumors that formed after LIN28A knockdown 
had morphological characteristics and LIN28A expression 
that was indistinguishable from pLKO-transduced 
cells. The increased latency of tumor formation that we 
identified after LIN28A knockdown was likely due to the 
vast majority of LIN28A knockdown cells being unable to 
grow. The tumors that did form were likely derived from a 
small population of BT37 cells that escaped from LIN28A 
knockdown. The universal expression of LIN28A in the 
BT37 pLKO and LIN28A knockdown tumors further 
supports the importance of LIN28 in AT/RT.
On a mechanistic level, LIN28A is known to 
regulate the let-7 family of microRNAs [21, 22]. 
Downregulation of let-7 has also been linked to human 
malignancies [23-27]. In our LIN28A knockdown 
experiments, we found LIN28A levels to be inversely 
correlated with let-7b and let-7g microRNA expression. 
We also found downregulation of KRAS mRNA and 
phospho-ERK signaling after LIN28A suppression. 
Identification of the RAS pathway as highly active in AT/
RT, and that MEK inhibition suppresses the growth of AT/
RT cells and induces apoptosis is consistent with recent 
findings of dysregulation of cyclin dependent kinases 
(CDKs) in AT/RT and an increasingly recognized role 
of LIN28 in regulating CDKs [28]. The frequent lack of 
expression of p16INK4a in AT/RT [29] is also consistent with 
an ability to tolerate high-level MAP kinase signaling and 
avoid oncogene induced senescence [30]. 
The broad expression of p-ERK suggests that MEK 
may be a therapeutic target in AT/RT. We found equal 
responses to the MEK-inhibitor selumetinib in BT37 
and CHLA06 (LIN28A-expressing) and BT12 (LIN28B-
expressing) cell lines, indicating that both LIN28A and 
LIN28B-expressing AT/RT may be sensitive to this class 
of pharmaceutical. Selumetinib is currently in phase I/II 
clinical trials in pediatric patients with low grade gliomas 
(NCT01089101). Additional, more potent, MEK inhibitors 
with improved brain penetration are also being tested in 
early phase trials in children (NCT02124772). 
In AT/RT there is a significant absence of mutations 
in canonical pathways normally implicated in aggressive 
cancer [4]. However, both SMARCB1 and LIN28A/B 
regulate large portions of the genome through chromatin 
remodeling and RNA stabilization respectively [31, 
32]. A recent study reported that LIN28 regulates more 
than 3,000 different RNA species, many of which are 
implicated in oncogenic pathways [33]. LIN28A and 
SMARCB1 can suppress senescence by regulating cell 
proliferation and growth pathways [6]. LIN28 is also able 
to adjust the metabolism of cells, promoting tumor growth 
and survival [34-36]. AT/RT is known to express multiple 
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stem cell markers, and may arise from stem cells [8, 20]. 
Persistent expression of LIN28 and other stem cell factors 
may be due to the cell of origin of AT/RT. SMARCB1 loss 
may lead to a block of differentiation and persistence of 
a stem-like state. The ability of LIN28 and SMARCB1 
to simultaneously regulate large sections of the genome 
and suppress senescence could spark the development of 
a malignant tumor such as AT/RT. 
In summary, our study demonstrates the importance 
of the LIN28/let-7 pathway in AT/RT. Knockdown of 
LIN28A using short hairpin RNA constructs resulted in 
a significant decrease in cell growth, proliferation, and 
clonogenic potential, as well as a corresponding induction 
of apoptosis. In orthotopic xenograft experiments, loss of 
LIN28A was sufficient to increase the latency of AT/RT 
tumor formation in immunodeficient mice. Investigation 
of LIN28A/let-7 targets in AT/RT demonstrated 
downregulation of KRAS after LIN28A knockdown, and 
we demonstrated the upregulation of KRAS downstream 
effectors by identifying phospho-ERK signaling in 
primary AT/RT. Inhibition of MEK by selumetinib in AT/
RT led to growth suppression and induction of apoptosis, 
indicating that this pathway may be a promising target 




The AT/RT cell lines CHLA-02-ATRT, CHLA-
04-ATRT, and CHLA-06-ATRT have been previously 
described [37]. CHLA-02-ATRT and CHLA-04-ATRT are 
available from ATCC (Manassas, VA). The BT37 AT/RT 
cell line was derived from a serially passaged xenograft 
derived from a patient with AT/RT. Cells were grown as 
semi-adherent cultures in RPMI/10% FBS media (500 
mL RPMI, 50 mL fetal bovine serum, 1% L-glutamine, 
1% Penicillin/Streptomycin, Life Technologies, Grand 
Island, NY). Cells were split at high density after scraping 
and gentle titration. BT12 cells (available through the 
Children’s Oncology Group cell repository, Lubbock, TX) 
were grown in RPMI/10% FBS media (500 mL RPMI, 50 
mL fetal bovine serum, 1% L-glutamine, 1% Penicillin/
Streptomycin. Selumetinib (AZD6244) was obtained 
from Selleck Chemicals (Houston, TX) and dissolved in 
DMSO. 
Viral infections and short hairpin constructs
Lentivirus vectors encoding short hairpin RNA 
constructs against LIN28A were purchased from 
Sigma-Aldrich (St. Louis, MO) (TRCN0000021800, 
TRCN0000021802 and TRCN00000803). To produce the 
required lentiviral particles, 293T cells were transfected 
with VSVG envelope plasmid, delta 8.9 gag/pol plasmid 
and the plasmid of interest using Fugene transfection 
reagent (Promega, Madison, WI) per the manufacturer’s 
instructions, as described previously [11]. Supernatants 
were then collected at 48 hours, 72 hours, and 96 hours 
and stored at 4 C. For infection of AT/RT cell lines, 
adherent cells and neurospheres were dissociated into 
single cells with gentle titration and Accutase (Sigma-
Aldrich), respectively, and incubated with the lentivirus 
containing LIN28A-shRNA, or pLKO empty vector. After 
48 hours in culture, infected cells were selected using 1 
ug/ml puromycin. All experiments were performed within 
14 days of infection of cells.
Immunofluorescence assays
For immunofluorescence assays, cells were cytospun 
onto positively charged slides (ThermoFisher Scientific, 
Waltham, MA), washed once with PBS, and fixed with 
4% paraformaldehyde for 15 minutes. After washing three 
times with PBST, cells were permeabilized with 0.1% 
Triton/PBS, blocked for 15 minutes with 5% normal goat 
serum/PBST, and then incubated with the cleaved caspase 
3 primary antibody (Cell Signaling Technology, Danvers, 
MA). Cells were then washed three times with PBST 
and incubated for 45 minutes in the dark with the Cy-3 
conjugated secondary antibody (Jackson Immunoresearch, 
West Grove, PA). Following this incubation, cells were 
counterstained with DAPI and mounted with anti-fade 
mounting media (Vectastain, Burlingame, CA).
Flow cytometry
Cells were fixed in ice cold 70% ethanol and 
processed according to the Guava cell cycle flow 
cytometry protocol (EMD Millipore, Billerica, MA). Data 
were captured on a Guava flow cytometer. 
Growth Assays
Bromodeoxyuridine incorporation assays were 
performed by incubating cells with 100 uM 5-bromo-2’-
deoxyuridine (BrdU, Sigma-Aldrich) for 6 hours. Cells 
were taken out of the BrdU medium, dissociated into 
single cells with gentle titration and Accutase, washed with 
PBS, and fixed with methanol overnight at 4 C. Cells were 
cytospun onto positively charged slides and processed as 
described above. Anti-BrdU antibody was used as per 
the manufacturer’s direction (Sigma-Aldrich, B2531) at 
1:500 dilution and visualized as described above. Results 
were analyzed in Adobe Photoshop, where BrdU-positive 
cells were counted using the count tool. To assess relative 
growth, cells were plated in 96-well plates in triplicate at 
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densities of 4000 cells per well. Relative cell number was 
then measured at 0, 2, 4, and 7 days using the colorimetric 
CellTiter 96 MTS assay (Promega).
Colony formation assay in soft agarose
Six-well plates were coated with a bottom agar/
media mixture, which was made from a 1:1 mixture of 
a prepared 2x concentration of neurosphere media and 
1 percent melted agarose (Life Technologies) in water. 
Cells were incubated in Accutase (Sigma-Aldrich), 
triturated into single cells, and placed into a top agarose/
media mixture (0.7%) an immediately plated into the 
6-well plates at a density of 20,000 cells/well in 1.5 
mL of agarose. 1.5 ml of media was then placed into 
each well. Fresh media was added every 7 days, and the 
colonies were grown for 1.5 to 2 weeks. Colonies were 
then visualized by staining with nitroblue tetrazolium 
(Sigma-Aldrich) overnight at 37 C and quantified using 
MCID Elite software (Cambridge, England, UK) with a 
gate diameter of 50 microns.
Quantitative RT-PCR
Relative RNA expression was analyzed by real-
time PCR analysis in triplicate with SYBER Green 
reagents (Applied Biosystems, Foster City, CA) per 
manufacturer’s instructions on an I-Cycler IQ5 real-
time detection system (Bio-Rad, Hercules, CA). 
Expression levels were determined using the delta/delta 
CT method and then normalized to either β-ACTIN 
or 18S rRNA. Primer sequences were as follows: 
human LIN28A forward: CGGGCATCTGTAAGT, 
reverse: CAGACCCTTGGCTGA; human β-ACTIN 
forward: CCCAGCACAATGAAGATCAA, reverse: 
GATCCACACGGAGTACTTG; human 18S 
forward: GTAACCCGTTGAACCCCATT, reverse: 
CCATCCAATCGGTAGTAGCG; human KRAS 
forward: GGGGAGGGCTTTCTTTGTGT, reverse: 
GTCCTGAGCCTGTTTTGTGTC. Relative expression 
of microRNAs, mature let-7a, b, and g were quantified 
using Taqman MicroRNA Assay (Life Technologies) per 
the manufacturer’s instructions. Expression levels were 
normalized to 18S rRNA.
Western blotting
Western blots were performed as previously 
described [11]. Specific antibodies were used as per the 
manufacturer’s instructions: LIN28A (Cell Signaling 
Technologies), β-ACTIN (Santa Cruz Biotechnology, Inc., 
Dallas, TX), GAPDH; Fitzgerald Industries, Acton, MA).
Intracranial xenograft tumors
For animal care and anesthesia, “Principles of 
laboratory animal care” (NIH publication No. 86-23, 
revised 1985) were followed, using a protocol approved 
by the Johns Hopkins Animal Care and Use Committee, 
in compliance with the United States Animal Welfare Act 
regulations and Public Health Service Policy. Intracranial 
xenografts were produced in anesthetized animals as 
previously described [11]. Injection guide holes were 
produced by an 18-gauge beveled needle and 1x105 viable 
cells were injected in 5 ul of growth medium into the right 
striatum stereotactically through a needle connected to a 
Hamilton syringe. Cells were injected using the following 
coordinates: antero-posterior = -3mm; medio-latral=2 
mm; dorso-ventral =3 mm. Animals were sacrificed 
upon signs of distress suggestive of an intracranial mass 
lesion such as neurologic deficits, poor grooming, and 
cachexia. Xenograft tumors were embedded in paraffin 
and processed for immunohistochemistry by the Johns 
Hopkins Histopathology Core.
Statistical Analysis
Statistical analysis was performed using GraphPad 
Prism (GraphPad Software, San Diego, California) or 
Excel (Microsoft, Redmond, WA). All tests were two sided 
unless indicated otherwise, and p values under 0.05 were 
considered significant unless otherwise indicated. Error 
bars on graphs are SEM unless otherwise indicated. 
Primary brain tumor samples
Brain tumor specimens were procured by the 
departments of pathology at Johns Hopkins University 
School of Medicine Department of Pathology, the 
Children’s Hospital of Philadelphia, and St. Jude 
Children’s Research Hospital with institutional review 
board approval. All samples were de-identified. 
Immunohistochemistry
Phospho-ERK antibody (Cell Signaling Technology) 
was used as described previously [38]. Anti-LIN28A (Cell 
Signaling Technology) was used as described previously 
[16]. AT/RT tissue cores were scored by a neuropathologist 
(CGE) using H-scores (H) (0–200) which were obtained 
by multiplying the intensity of stain (0: no stain, 1: weak 
stain, 2: strong stain) by percentage (0–100) of neoplastic 
cells showing the staining intensity. Tumors were scored 
for phospho-ERK and LIN28A as being negative (score 
of 0), low (5 to 45), intermediate (50-95) or high (100 and 
above). 
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LIN28 and let-7 RNA quantification
Total RNA was extracted from frozen brain tumors 
using the Qiagen miRNeasy kit (Qiagen, Valencia, CA) 
according to the manufacturer’s instructions. The quantity 
and quality of the RNA was determined using a Nanodrop 
1000 (ThermoFisher Scientific). 
Quantitative RT-PCR was used to determine the 
relative expression of LIN28A and LIN28B in both 
primary AT/RT and pilocytic astrocytoma (PA) brain 
tumor samples. Expression levels were determined using 
the delta/delta Ct method on the ABI 7500 FAST real-
time detection system with the Taqman assays, LIN28A 
– Hs00702808_s1 and LIN28B – hs01013729_m1, as per 
the manufacturer’s guidelines (Applied Biosystems). All 
samples were run in triplicate and GAPDH was used as the 
endogenous control for the normalization. 
A total of 45 RNA samples, 26 AT/RT and 18 PA, 
were submitted to Nanostring for microRNA expression 
analysis using the microRNA nCounter assay (version 
1), which measured the expression level of 654 human 
microRNAs (Nanostring, Seattle, WA). 
The raw Nanostring data were analyzed using the 
methods described in the nCounter Expression Data 
Analysis Guide (http://www.nanostring.com/media/pdf/
MAN_nCounter_Gene_Expression_Data_Analysis_
Guidelines.pdf). In the first round of analysis, the 
technical reproducibility of the assay was assessed, and 
one lane from each set of technical replicates was chosen 
to represent the tumor in the second round of analysis. 
The steps for the two rounds of analysis consisted of 
(i) calculating the average value of all negative probes 
across all tumor samples; (ii) calculating the geometric 
mean for each sample from the overall top 100 expressing 
microRNAs; (iii) performing a lane normalization using 
the normalization factor determined by the average 
geometric mean for the entire assay; (iv) determining the 
negative threshold for the assay by calculating the mean 
+2 standard deviation of the negative control probes for 
each lane and then averaging these values across the assay. 
The Pearson correlation was used at the end of 
the first round of analysis to determine the technical 
reproducibility of the assay. A correlation value above 
0.95 was considered highly correlated. A random 
number generator was then used to select the lane that 
was representative of each tumor in the second round of 
analysis. The microRNA counts determined at the end of 
the two rounds of analysis were then used for downstream 
statistical analyses in GraphPad Prism. 
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